Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company.
A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Super Grp (SGHC) Ltd | Alon Ben-David | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2026 | 116,747 | 116,747 | - | - | Restricted Stock Unit (RSUs) | |
| Super Grp (SGHC) Ltd | Alon Ben-David | Chief Technology Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 12 Jun 2026 | 116,747 | 116,747 | - | - | Restricted Stock Unit (RSUs) | |
| Stoneridge Inc | William M. Lasky | Director | Purchase of securities on an exchange or from another person at price $ 7.46 per share. | 12 Jun 2026 | 5,000 | 192,666 (0%) | 0% | 7.5 | 37,300 | Common Shares, without par value |
| NBT Bancorp. Inc | Heidi M. Hoeller | Director | Sale of securities on an exchange or to another person at price $ 48.04 per share. | 12 Jun 2026 | 2,100 | 11,560 (0%) | 0% | 48.0 | 100,874 | NBT Bancorp Inc. Common Stock |
| Mawson infra Grp Inc | K. Rodger Davis | Director | Purchase of securities on an exchange or from another person at price $ 7.04 per share. | 12 Jun 2026 | 2,000 | 2,000 | - | 7.0 | 14,080 | Common Stock |
| Banner Corp | James P.G. McLean | Executive VP, Banner Bank | Sale or transfer of securities back to the company at price $ 67.16 per share. | 12 Jun 2026 | 1,800 | 22,393 (0%) | 0% | 67.2 | 120,888 | Common Stock, $0.01 par value per share |
| NBT Bancorp. Inc | Martin Randolph Sparks | EVP,General Counsel,Secretary | Sale of securities on an exchange or to another person at price $ 48.04 per share. | 12 Jun 2026 | 1,200 | 14,462 (0%) | 0% | 48.0 | 57,650 | NBT Bancorp Inc. Common Stock |
| Northwest Pipe Co. | John T. Paschal | Director | Grant, award, or other acquisition of securities at price $ 122.31 per share. | 12 Jun 2026 | 899 | 17,098 (0%) | 0% | 122.3 | 109,957 | Common Stock |
| Preformed Line Products Co | Andrew S. Klaus | CFO | Sale or transfer of securities back to the company at price $ 362.22 per share. | 12 Jun 2026 | 635 | 13,918 (0%) | 0% | 362.2 | 230,010 | Common shares, $2 par value |
| Fidelity D&D Bancorp Inc | Brian J. Cali | Director, Chairman of the Board | Purchase of securities on an exchange or from another person at price $ 0.00 per share. | 12 Jun 2026 | 273 | 426,138 (11%) | 0% | - | Common Stock | |
| APi Grp Corp | Martin E. Franklin | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 42.08 per share. | 11 Jun 2026 | 2,000,000 | 19,240,426 | - | 42.1 | 84,160,000 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 479,989 | 0 (0%) | 2% | 0 | Common Stock | |
| Garmin | Jonathan C. Burrell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Jun 2026 | 322,000 | 322,000 (0%) | 0% | 0 | Registered Shares | |
| Garmin | Jonathan C. Burrell | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Jun 2026 | 322,000 | 4,269,752 (2%) | 0% | 0 | Registered Shares | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 304,688 | 0 | - | - | Restricted Stock Unit | |
| Nerdy Inc (Class A) | Charles Cohn | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.97 per share. | 11 Jun 2026 | 258,204 | 477,223 | - | 1.0 | 250,458 | Class A Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 255,750 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 229,918 | 0 (0%) | 1% | 0 | Common Stock | |
| Cosmos Health Inc | Grigorios Siokas | Director, Chief Executive Officer, Ten Percent Owner | Purchase of securities on an exchange or from another person at price $ 0.21 per share. | 11 Jun 2026 | 218,447 | 13,481,808 | - | 0.2 | 45,000 | Common Stock, par value $.001 |
| Silvaco Grp Inc | Katherine S. Ngai-Pesic | Director, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 11.27 per share. | 11 Jun 2026 | 200,000 | 9,176,403 | - | 11.3 | 2,254,320 | Common Stock |
| KalVista Pharma Inc | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 150,260 | 0 (0%) | 0% | 0 | Common Stock | |
| Yext Inc | Seth H. Waugh | Director | Purchase of securities on an exchange or from another person at price $ 3.75 per share. | 11 Jun 2026 | 133,000 | 319,411 (0%) | 0% | 3.7 | 498,218 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 125,001 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 113,920 | 0 | - | - | Stock Option (Right to Buy) | |
| AbCellera Biologics Inc | Michael Hayden | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 111,701 | 1,011,544 | - | - | Share option (right to buy) | |
| AbCellera Biologics Inc | John S. Montalbano | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 111,701 | 1,141,544 | - | - | Share option (right to buy) | |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Bilal Arif | Chief Operations Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 100,000 | 0 | - | - | Stock Option (Right to Buy) | |
| StepStone Grp Inc (Class A) | Michael I. McCabe | Director, Head of Strategy | Purchase of securities on an exchange or from another person at price $ 41.71 per share. | 11 Jun 2026 | 96,887 | 410,065 | - | 41.7 | 4,041,157 | Class A Common Stock |
| Vita Coco Co Inc | Ira Liran | Director | Sale of securities on an exchange or to another person at price $ 79.14 per share. | 11 Jun 2026 | 96,158 | 476,421 | - | 79.1 | 7,609,944 | Common Stock |
| Vita Coco Co Inc | Ira Liran | Director | Sale of securities on an exchange or to another person at price $ 79.14 per share. | 11 Jun 2026 | 95,768 | 384,103 | - | 79.1 | 7,579,080 | Common Stock |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 93,750 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 93,750 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 93,750 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 92,560 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 85,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 80,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 75,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 71,700 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 68,750 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 68,750 | 0 | - | - | Restricted Stock Unit | |
| Liberty Global PLC (Class A) | Charles H.R. Bracken | EVP & CFO | Sale of securities on an exchange or to another person at price $ 11.60 per share. | 11 Jun 2026 | 62,448 | 19,953 (0%) | 0% | 11.6 | 724,690 | Class C Common Shares |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 60,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 59,291 | 0 (0%) | 0% | 0 | Common Stock | |
| SentinelOne Inc (Class A) | Tomer Weingarten | Director, President, CEO | Sale of securities on an exchange or to another person at price $ 14.60 per share. | 11 Jun 2026 | 57,296 | 1,894,397 | - | 14.6 | 836,275 | Class A Common Stock |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 55,000 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 53,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Liberty Global PLC (Class A) | Charles H.R. Bracken | EVP & CFO | Sale of securities on an exchange or to another person at price $ 12.03 per share. | 11 Jun 2026 | 53,011 | 19,953 (0%) | 0% | 12.0 | 637,611 | Class A Common Shares |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 52,600 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 52,600 | 0 | - | - | Stock Option (Right to Buy) | |
| TFS Fin Corp | Meredith S. Weil | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 14.74 per share. | 11 Jun 2026 | 50,000 | 88,480 (0%) | 0% | 14.7 | 737,000 | Common Stock |
| TFS Fin Corp | Meredith S. Weil | Director, Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2026 | 50,000 | 57,500 | - | - | Employee Stock Option (right to buy) | |
| KalVista Pharma Inc | Bilal Arif | Chief Operations Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 49,000 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 47,354 | 0 | - | - | Stock Option (Right to Buy) | |
| BKV Corp | Lindsay B. Larrick | Chief Legal and Admin Officer | Other type of transaction at price $ 0.00 per share. | 11 Jun 2026 | 45,839 | 93,925 | - | 0 | Common Stock | |
| TFS Fin Corp | Meredith S. Weil | Director, Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 16.80 per share. | 11 Jun 2026 | 45,684 | 42,796 (0%) | 0% | 16.8 | 767,491 | Common Stock |
| KalVista Pharma Inc | Bethany L. Sensenig | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 45,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 41,250 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 40,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nicole Sweeny | Chief Commercial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 40,000 | 0 | - | - | Restricted Stock Unit | |
| KalVista Pharma Inc | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 40,000 | 0 | - | - | Restricted Stock Unit | |
| Sprout Social Inc (Class A) | Justyn Howard | Director, Executive Chair, Ten Percent Owner | 11 Jun 2026 | 40,000 | 47,417 (0%) | 0% | 0 | Class A Common Stock | ||
| Sprout Social Inc (Class A) | Justyn Howard | Director, Executive Chair, Ten Percent Owner | 11 Jun 2026 | 40,000 | 1,441,190 | - | - | Class B Common Stock | ||
| Sprout Social Inc (Class A) | Justyn Howard | Director, Executive Chair, Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 6.99 per share. | 11 Jun 2026 | 40,000 | 7,417 (0%) | 0% | 7.0 | 279,680 | Class A Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 37,500 | 0 | - | - | Stock Option (Right to Buy) | |
| Nuvectis Pharma Inc | James F. Oliviero | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 35,000 | 122,828 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Kenneth Hoberman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 35,000 | 168,140 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Juan F Sanchez | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 35,000 | 113,380 | - | 0 | Common Stock | |
| Nuvectis Pharma Inc | Matthew L. Kaplan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 35,000 | 159,760 | - | 0 | Common Stock | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 33,800 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 33,750 | 0 | - | - | Stock Option (Right to Buy) | |
| Immuneering Corp (Class A) | Laurie B. Keating | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 33,350 | 33,350 | - | - | Stock Option | |
| Immuneering Corp (Class A) | Robert J. Carpenter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 33,350 | 33,350 | - | - | Stock Option | |
| Immuneering Corp (Class A) | Diana F. Hausman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 33,350 | 33,350 | - | - | Stock Option | |
| Immuneering Corp (Class A) | Thomas J. Schall | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 33,350 | 33,350 | - | - | Stock Option | |
| Immuneering Corp (Class A) | Peter Feinberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 33,350 | 33,350 | - | - | Stock Option | |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 31,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Cinemark Holdings Inc | Valmir Fernandes | Pr - Cinemark International | Sale or transfer of securities back to the company at price $ 33.50 per share. | 11 Jun 2026 | 30,000 | 126,386 (0%) | 0% | 33.5 | 1,005,000 | Common Stock |
| Vita Coco Co Inc | Jonathan Burth | Chief Operating Officer | Sale of securities on an exchange or to another person at price $ 80.00 per share. | 11 Jun 2026 | 30,000 | 57,910 | - | 80 | 2,400,000 | Common Stock |
| KalVista Pharma Inc | Brian J.G. Pereira | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nancy Stuart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | William Carl Fairey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Patrick Treanor | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 30,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 29,611 | 0 | - | - | Stock Option (Right to Buy) | |
| Seadrill Ltd | Grant Russel Creed | Executive Vice President & CFO | Sale of securities on an exchange or to another person at price $ 44.92 per share. | 11 Jun 2026 | 27,952 | 23,064 | - | 44.9 | 1,255,604 | Common Shares |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 27,900 | 0 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Andrew N. Schiff | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 25,800 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Anthony M. Manning | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 25,800 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Christine Siu | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 25,800 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Jan Skvarka | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 25,800 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Kimberly L. Blackwell | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 25,800 | - | - | Stock Option (Right to Buy) | |
| Monte Rosa Therapeutics Inc | Eric A Hughes | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 25,800 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Paul K. Audhya | CHIEF MEDICAL OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 25,800 | 0 | - | - | Stock Option (Right to Buy) | |
| Alignment Healthcare Inc | Joseph Konowiecki | Director, EVP, Corporate Affairs | Sale of securities on an exchange or to another person at price $ 21.00 per share. | 11 Jun 2026 | 25,000 | 1,178,816 | - | 21 | 525,000 | Common Stock |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 25,000 | 0 | - | - | Restricted Stock Unit | |
| NeoVolta Inc | John Hass | Director | Purchase of securities on an exchange or from another person at price $ 1.92 per share. | 11 Jun 2026 | 25,000 | 101,190 | - | 1.9 | 48,000 | Common Stock |
| Lee Enterprises Inc | Herbert W. Moloney | Director | Sale of securities on an exchange or to another person at price $ 9.82 per share. | 11 Jun 2026 | 24,000 | 23,037 (0%) | 0% | 9.8 | 235,680 | Common Stock |
| Vita Coco Co Inc | Jonathan Burth | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.18 per share. | 11 Jun 2026 | 23,575 | 81,485 | - | 10.2 | 239,946 | Common Stock |
| Vita Coco Co Inc | Jonathan Burth | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2026 | 23,575 | 0 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| StepStone Grp Inc (Class A) | Michael I. McCabe | Director, Head of Strategy | Purchase of securities on an exchange or from another person at price $ 42.44 per share. | 11 Jun 2026 | 23,113 | 433,178 | - | 42.4 | 980,916 | Class A Common Stock |
| KalVista Pharma Inc | Brian Piekos | Chief Financial Officer | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 21,661 | 0 (0%) | 0% | 0 | Common Stock | |
| Benchmark Electronics Inc | Stephen J. Beaver | SVP, General Counsel and CLO | Sale of securities on an exchange or to another person at price $ 86.25 per share. | 11 Jun 2026 | 20,000 | 75,020 (0%) | 0% | 86.3 | 1,725,000 | Common Stock |
| KalVista Pharma Inc | Benjamin L. Palleiko | Director, CHIEF EXECUTIVE OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 20,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Christopher M. Yea | CHIEF DEVELOPMENT OFFICER | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 18,920 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Laurence E. Reid | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 17,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | William Carl Fairey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 17,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Patrick Treanor | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 17,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Brian J.G. Pereira | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 14,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nancy Stuart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 14,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Seadrill Ltd | Marcel Wieggers | Senior VP, Operations | Sale of securities on an exchange or to another person at price $ 44.94 per share. | 11 Jun 2026 | 13,474 | 1 | - | 44.9 | 605,522 | Common Shares |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 12,000 | 0 | - | - | Stock Option (Right to Buy) | |
| American Superconductor Corp | Daniel P. McGahn | Director, Chairman, President and CEO | Sale of securities on an exchange or to another person at price $ 37.28 per share. | 11 Jun 2026 | 11,508 | 1,136,538 (5%) | 0% | 37.3 | 429,047 | Common Stock |
| Tillys Inc (Class A) | Michael Joseph Cingolani | Chief Merchandising Officer | Sale of securities on an exchange or to another person at price $ 5.27 per share. | 11 Jun 2026 | 11,250 | 113,750 (0%) | 0% | 5.3 | 59,284 | Class A Common Stock |
| East West Bancorp Inc | Irene H. Oh | Chief Risk Officer | Sale of securities on an exchange or to another person at price $ 129.00 per share. | 11 Jun 2026 | 11,211 | 85,998 (0%) | 0% | 129 | 1,446,219 | Common Stock |
| Dare Bioscience Inc | Robin J. Steele | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Dare Bioscience Inc | William H. Rastetter | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Dare Bioscience Inc | Gregory W. Matz | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Dare Bioscience Inc | Susan L. Kelley | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| Dare Bioscience Inc | Jessica D. Grossman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 10,000 | - | - | Stock Option (right to buy) | |
| DXP Enterprises Inc | Paz Maestas | CMO & CTO | Sale of securities on an exchange or to another person at price $ 164.37 per share. | 11 Jun 2026 | 10,000 | 590,262 (3%) | 0% | 164.4 | 1,643,700 | DXP Common Stock |
| KalVista Pharma Inc | Brian J.G. Pereira | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Brian J.G. Pereira | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Brian J.G. Pereira | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Brian J.G. Pereira | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nancy Stuart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nancy Stuart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Nancy Stuart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | William Carl Fairey | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Patrick Treanor | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Patrick Treanor | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 10,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Spar Grp Inc | Robert G. Brown | Ten Percent Owner | Sale of securities on an exchange or to another person at price $ 0.85 per share. | 11 Jun 2026 | 10,000 | 2,881,389 (13%) | 0% | 0.9 | 8,500 | Common Stock, $.01 par value |
| Vroom Inc - Ordinary Shares- New | Robert J. Mylod | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 9,832 | 20,117 | - | 0 | Common Stock | |
| Vroom Inc - Ordinary Shares- New | Timothy M. Crow | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 9,832 | 18,080 | - | 0 | Common Stock | |
| Vroom Inc - Ordinary Shares- New | Robert R. Krakowiak | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 9,832 | 21,071 | - | 0 | Common Stock | |
| Church & Dwight | Robert K. Shearer | Director | Sale of securities on an exchange or to another person at price $ 97.97 per share. | 11 Jun 2026 | 8,600 | 30,678 (0%) | 0% | 98.0 | 842,543 | Common Stock |
| Church & Dwight | Robert K. Shearer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2026 | 8,600 | 0 | - | - | Stock Option (right to buy) | |
| Church & Dwight | Robert K. Shearer | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 77.33 per share. | 11 Jun 2026 | 8,600 | 39,278 (0%) | 0% | 77.3 | 665,038 | Common Stock |
| Clover Health Investments Corp (Class A) | Jamie L. Reynoso | CEO, Medicare Advantage | Sale of securities on an exchange or to another person at price $ 4.91 per share. | 11 Jun 2026 | 7,289 | 2,849,921 | - | 4.9 | 35,789 | Class A Common Stock |
| BKV Corp | Charles C. Miller | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 7,128 | 12,889 | - | 0 | Common Stock | |
| BKV Corp | Carla S. Mashinski | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 7,128 | 12,889 | - | 0 | Common Stock | |
| BKV Corp | Sunit S. Patel | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 7,128 | 62,889 | - | 0 | Common Stock | |
| BKV Corp | Kirana Limpaphayom | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 7,128 | 7,128 | - | 0 | Common Stock | |
| BKV Corp | Joseph R. Davis | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 7,128 | 45,889 | - | 0 | Common Stock | |
| KalVista Pharma Inc | Brian J.G. Pereira | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 7,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 7,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 7,000 | 0 | - | - | Stock Option (Right to Buy) | |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 7,000 | 0 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | Gwendolyn K. Binder | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 6,500 | 6,500 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | R. Kent McGaughy | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 6,500 | 6,500 | - | - | Stock Option (Right to Buy) | |
| Instil Bio Inc | George Matcham | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 6,500 | 6,500 | - | - | Stock Option (Right to Buy) | |
| Vita Coco Co Inc | Jonathan Burth | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 10.18 per share. | 11 Jun 2026 | 6,425 | 87,910 | - | 10.2 | 65,394 | Common Stock |
| Vita Coco Co Inc | Jonathan Burth | Chief Operating Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2026 | 6,425 | 34,525 | - | - | Non-Qualified Stock Option (Right to Buy) | |
| Seadrill Ltd | Grant Russel Creed | Executive Vice President & CFO | Sale of securities on an exchange or to another person at price $ 44.20 per share. | 11 Jun 2026 | 6,195 | 51,016 | - | 44.2 | 273,819 | Common Shares |
| KalVista Pharma Inc | Edward W. Unkart | Director | Sale or transfer of securities back to the company at price $ 0.00 per share. | 11 Jun 2026 | 6,000 | 0 | - | - | Stock Option (Right to Buy) | |
| American Superconductor Corp | John W. Kosiba | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 37.33 per share. | 11 Jun 2026 | 5,026 | 336,120 (1%) | 0% | 37.3 | 187,604 | Common Stock |
| Xilio Therapeutics Inc | Sara M. Bonstein | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Aoife M. Brennan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Daniel Curran | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| Xilio Therapeutics Inc | Akintunde Bello | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 5,000 | 5,000 | - | - | Stock Option (right to buy) | |
| American Superconductor Corp | Daniel P. McGahn | Director, Chairman, President and CEO | Sale of securities on an exchange or to another person at price $ 37.85 per share. | 11 Jun 2026 | 4,609 | 1,131,929 (5%) | 0% | 37.9 | 174,456 | Common Stock |
| Corpay | Armando Lins Netto | GroupPresident Brazil&USVehPmt | Sale of securities on an exchange or to another person at price $ 351.60 per share. | 11 Jun 2026 | 4,560 | 11,274 (0%) | 0% | 351.6 | 1,603,307 | Common Stock |
| KLA | Richard P. Wallace | President and CEO | Sale of securities on an exchange or to another person at price $ 2213.37 per share. | 11 Jun 2026 | 4,512 | 71,383 (0%) | 0% | 2213.4 | 9,986,725 | Common Stock |
| Powell Industries Inc | Brett A. Cope | Director, President & CEO | Sale of securities on an exchange or to another person at price $ 272.64 per share. | 11 Jun 2026 | 4,440 | 485,673 (4%) | 0% | 272.6 | 1,210,522 | Common Stock |
| TFS Fin Corp | Meredith S. Weil | Director, Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.80 per share. | 11 Jun 2026 | 4,316 | 38,480 (0%) | 0% | 16.8 | 72,509 | Common Stock |
| Outfront Media Inc | James Michael Norton | EVP, CRO, Enterprise | Purchase of securities on an exchange or from another person at price $ 30.81 per share. | 11 Jun 2026 | 4,130 | 4,130 (0%) | 0% | 30.8 | 127,245 | Common Stock |
| Build A Bear Workshop Inc | Craig A. Leavitt | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 3,698 | 67,840 (0%) | 0% | - | Common Stock | |
| Cinemark Holdings Inc | Humrichouse G Ximena | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Jun 2026 | 3,503 | 51,783 (0%) | 0% | 0 | Common Stock | |
| Kearny Fin Corp | Melvina Wong-Zaza | Director | Purchase of securities on an exchange or from another person at price $ 8.58 per share. | 11 Jun 2026 | 3,500 | 33,910 (0%) | 0% | 8.6 | 30,013 | Common Stock |
| Build A Bear Workshop Inc | James A. Goldman | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 2,663 | 3,219 (0%) | 0% | - | Common Stock | |
| Build A Bear Workshop Inc | Richard A. Johnson | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 2,663 | 5,124 (0%) | 0% | - | Common Stock | |
| Build A Bear Workshop Inc | George M. Carrara | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 2,663 | 13,940 (0%) | 0% | - | Common Stock | |
| Build A Bear Workshop Inc | Sharon Price John | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 2,663 | 221,807 (1%) | 0% | - | Common Stock | |
| Build A Bear Workshop Inc | Narayan Raghu Iyengar | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 2,663 | 18,716 (0%) | 0% | - | Common Stock | |
| Build A Bear Workshop Inc | Lesli Rotenberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 2,663 | 12,488 (0%) | 0% | - | Common Stock | |
| Catalyst Bancorp Inc | Todd A. Kidder | Director, CHAIRMAN OF THE BOARD | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 2,645 | 2,645 | - | - | Stock Option (Right to Buy) | |
| Codexis Inc | Raymond de Vre | Director | Sale of securities on an exchange or to another person at price $ 2.37 per share. | 11 Jun 2026 | 2,605 | 84,811 (0%) | 0% | 2.4 | 6,174 | Common Stock |
| Littelfuse Inc | Anthony Grillo | Director | Sale of securities on an exchange or to another person at price $ 451.93 per share. | 11 Jun 2026 | 2,462 | 65,175 (0%) | 0% | 451.9 | 1,112,652 | Common Stock |
| Equity Bancshares Inc (Class A) | Jerry P. Maland | Director | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Jun 2026 | 2,228 | 17,863 (0%) | 0% | 0 | Class A Common Stock | |
| Johnson Outdoors Inc (Class A) | John M. Fahey | Director | Sale of securities on an exchange or to another person at price $ 45.80 per share. | 11 Jun 2026 | 2,000 | 18,103 (0%) | 0% | 45.8 | 91,600 | Class A Common Stock |
| Peapack-Gladstone Fin Corp | Francesco S. Rossi | SVP/Chief Accounting Officer | Sale of securities on an exchange or to another person at price $ 45.52 per share. | 11 Jun 2026 | 1,937 | 3,370 (0%) | 0% | 45.5 | 88,164 | Common Stock |
| Ducommun Inc | Stephen G. Oswald | Director, Chairman, President & CEO | Gift of securities by or to the insider at price $ 0.00 per share. | 11 Jun 2026 | 1,920 | 385,875 (3%) | 0% | 0 | Common Stock | |
| Republic Services | Sandra M. Volpe | Director | Sale of securities on an exchange or to another person at price $ 211.28 per share. | 11 Jun 2026 | 1,800 | 58 (0%) | 0% | 211.3 | 380,304 | Common Stock |
| American Superconductor Corp | John W. Kosiba | SVP, CFO & Treasurer | Sale of securities on an exchange or to another person at price $ 37.85 per share. | 11 Jun 2026 | 1,743 | 334,377 (1%) | 0% | 37.9 | 65,975 | Common Stock |
| Equity Bancshares Inc (Class A) | Brett A. Reber | General Counsel | Sale of securities on an exchange or to another person at price $ 47.85 per share. | 11 Jun 2026 | 1,686 | 34,495 (0%) | 0% | 47.8 | 80,675 | Class A Common Stock |
| IRIDEX Corp | Romeo R. Dizon | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 1.14 per share. | 11 Jun 2026 | 1,675 | 135,000 (0%) | 0% | 1.1 | 1,910 | Common Stock |
| Legence Corp Ordinary | David J. Coghlan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 1,675 | 5,454 | - | 0 | Class A Common Stock | |
| Legence Corp Ordinary | Christie B. Kelly | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 1,675 | 7,032 | - | 0 | Class A Common Stock | |
| Legence Corp Ordinary | Terrence Keenen | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Jun 2026 | 1,675 | 15,960 | - | 0 | Class A Common Stock | |
| Kulicke & Soffa Ind Inc | Peter T. Kong | Director | Sale of securities on an exchange or to another person at price $ 110.00 per share. | 11 Jun 2026 | 1,551 | 100,009 (0%) | 0% | 110 | 170,610 | Common Stock |
| Hoyne Bancorp Inc | Walter F. Healy | Director, President, CEO and Director | Purchase of securities on an exchange or from another person at price $ 16.28 per share. | 11 Jun 2026 | 1,537 | 15,821 | - | 16.3 | 25,022 | Common Stock |
| Mawson infra Grp Inc | Kyle B. Danges | Director | Purchase of securities on an exchange or from another person at price $ 7.13 per share. | 11 Jun 2026 | 1,227 | 3,000 | - | 7.1 | 8,751 | Common Stock |
This section tracks all disclosures required by the U.S. Securities and Exchange Commission (SEC) under the Securities Exchange Act of 1934, particularly those related to Section 16 and Rule 10b-5, which govern insider trading activities in the U.S. market. These disclosures are made by corporate insiders, including executives, officers, directors, significant employees, and large shareholders, who are buying and selling stock in their own companies. You can search and filter within these results. You can also sort the information by clicking on the column headers.